Redeye continues to see good cost control and highlights that the low y/y sales growth can be partly explained by a shift in revenue recognition in Q3. While we argue that the company is developing well, we reconsider our long-term sales forecast (contingent on a US launch of UBC Rapid/TK210 ELISA) and make downward changes.
LÄS MER